H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Clene (CLNN – Research Report) today and set a price target of $31.00.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising potential of Clene’s CNM-Au8 treatment for multiple sclerosis (MS). The recent data presented at the American Academy of Neurology Annual Meeting 2025 showcased significant improvements in vision, cognition, and overall neurological function in patients treated with CNM-Au8 over a long-term period. These results were derived from the VISIONARY-MS OLE study, which demonstrated the treatment’s ability to repair and remyelinate neuronal tissue, as evidenced by MRI assessments.
Furthermore, the analyses revealed that a high percentage of patients experienced visual and cognitive benefits, supported by improvements in markers of tissue microstructure and integrity such as axial diffusivity and magnetization transfer ratio. These findings suggest that CNM-Au8 not only enhances axonal integrity but also offers sustained anatomical and physiological improvements, making it a compelling candidate for disease modification in MS. Pantginis’s rating reflects confidence in the long-term efficacy and potential market impact of Clene’s therapeutic approach.
According to TipRanks, Pantginis is an analyst with an average return of -22.8% and a 20.72% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Viking Therapeutics, and Actinium Pharmaceuticals.
In another report released on March 25, Roth MKM also maintained a Buy rating on the stock with a $30.00 price target.